Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2009-5-18
pubmed:abstractText
Acquired resistance to protein kinase C (PKC) modulators may explain the failure of clinical trials in patients with cancer. Herein, we established a human colon cancer cell line resistant to PEP005, a drug that inhibits PKCalpha and activates PKCdelta. Colo205-R cells, selected by stepwise exposure to PEP005, were >300-fold more resistant to PEP005 than parental Colo205-S cells and were cross-resistant to phorbol 12-myristate 13-acetate, bryostatin, bistratene A, and staurosporine. No PKCalpha or PKCdelta mutation was detected in Colo205-S and Colo205-R cells. Changes in Colo205-R cells were reminiscent of the epithelial-to-mesenchymal transition (EMT) phenotype. Accordingly, Colo205-R cells were more invasive than Colo205-S in Matrigel assays and in mouse xenografts. We also found an increased mRNA expression of several EMT genes, such as those encoding for transforming growth factor-beta and vimentin, along with a decreased mRNA expression of genes involved in epithelial differentiation, such as CDH1 (E-cadherin), CLDN4 (claudin 4), S100A4, and MUC1, in Colo205-R compared with Colo205-S cells in vitro and in vivo. Interestingly, high expression of ET-1 was shown in Colo205-R cells and correlated with low sensitivity to PEP005 and staurosporine in a panel of 10 human cancer cell lines. Inhibition of the ET-1 receptor ETR-A with bosentan restored the antiproliferative effects of PEP005 in Colo205-R cells and decreased the invasive properties of this cell line. Exogenous exposure to ET-1 and silencing ET-1 expression using small interfering RNA modulated cell signaling in Colo205-S and Colo205-R. In summary, acquired resistance to PEP005 was associated with expression of EMT markers and activates the ET-1/ETR-A cell signaling.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1538-7445
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4260-9
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:19417139-Animals, pubmed-meshheading:19417139-Breast Neoplasms, pubmed-meshheading:19417139-Cell Differentiation, pubmed-meshheading:19417139-Cell Division, pubmed-meshheading:19417139-Cell Line, Tumor, pubmed-meshheading:19417139-Cell Survival, pubmed-meshheading:19417139-Colonic Neoplasms, pubmed-meshheading:19417139-Diterpenes, pubmed-meshheading:19417139-Epithelial Cells, pubmed-meshheading:19417139-Exons, pubmed-meshheading:19417139-Female, pubmed-meshheading:19417139-Humans, pubmed-meshheading:19417139-Matrix Metalloproteinases, pubmed-meshheading:19417139-Mesoderm, pubmed-meshheading:19417139-Mice, pubmed-meshheading:19417139-Mice, Nude, pubmed-meshheading:19417139-Neoplasm Invasiveness, pubmed-meshheading:19417139-Ovarian Neoplasms, pubmed-meshheading:19417139-Protein Kinase C-alpha, pubmed-meshheading:19417139-Protein Kinase C-delta, pubmed-meshheading:19417139-RNA, Messenger, pubmed-meshheading:19417139-RNA, Small Interfering, pubmed-meshheading:19417139-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:19417139-Transplantation, Heterologous
pubmed:year
2009
pubmed:articleTitle
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
pubmed:affiliation
Institut National de la Sante et de la Recherche Medicale U728, RayLab, and Department of Medical Oncology, Beaujon and Saint-Louis University Hospital (AP-HP-Paris 7 Diderot), Clichy, France.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't